Bisphosphonates May Be Useful as Palliative Measure in Selected Patients
the ONA take:
Bisphosphonates may improve symptoms of hypercalcemia and prolong survival in patients with malignancy-associated hypercalcemia receiving palliative care, a new study published online ahead of print in the journal Supportive Care in Cancer has shown.
Because hypercalcemia can be a potentially fatal paraneoplastic complication of malignancy, researchers sought to determine the reversibility of hypercalcemia amongst patients not receiving treatment for their underlying malignancy and assess whether calcium correction improves symptoms.
For the study, researchers analyzed data from 63 patients with evidence of malignancy-associated hypercalcemia being treated with bisphosphonates. Results showed that 36 of the 63 participants achieved normal calcium levels following treatment with an intravenous bisphosphonate.
Researchers found that history of hypercalcemia in the past, age, and albumin levels impacted whether patients achieved a complete response. The study also demonstrated that a reduction in calcium level was associated with significantly improved survival and symptoms regardless of whether patients achieved normal calcium levels.
Malignancy-associated hypercalcemia typically manifests during the advanced phase of cancer, when the life expectancy of patients ranges from weeks to months.
Although bisphosphonates are the mainstay of treatment for this complication, they are not typically used in a palliative population.
Bisphosphonates may improve symptoms of hypercalcemia and prolong survival in patients receiving palliative care.
Sign Up for Free e-newsletters
- Triplet Regimen Found Most Effective for Relapsed/Refractory Multiple Myeloma
- Integrating Preoperative Oral Care Into Cancer Treatment Plans
- Current Status and Dilemma of Second-line Treatment in Advanced Pancreatic Cancer: Is There a Silver Lining?
- American Association for Cancer Research Releases Its 2018 Annual Report
- Pulmonary Toxicity Increased in Pediatric Hodgkin Lymphoma Treated With Brentuximab Vedotin
- Benefit of Chemotherapy for Breast Cancer Observed With Midrange Gene Assay Score
- Antioxidant Interaction With Cancer Therapy
- Young Survivors of Breast Cancer Report Sexual Quality of Life Declines After Treatment
- Myeloablative Conditioning Effective in AML Secondary to MDS/MPN Prior to Allogeneic HCT
- Insurance Status Influences Overall Survival in Follicular Lymphoma
- Endocrine Society Released Guidelines for Managing Endocrine Disorders in Childhood Cancer Survivors
- Skin Cancer Screening: Are They Effective?
- Metronidazole, Vancomycin Recommended for C Difficile in Pediatric Oncology, HSCT
- CDC: HPV Vaccination Rates on the Rise Among Adolescents
- High-Dose vs Standard-Dose Flu Vaccine in Elderly Receiving Chemotherapy
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|